Navigation Links
d'Oliveira & Associates Issues New Infographic on Xarelto Providing Current FDA and Medical Study Information
Date:3/25/2013

(PRWEB) March 25, 2013

In July of 2011, the FDA announced that it had approved Xarelto to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery (i). In November, the FDA expanded Xarelto’s approval to include the prevention of stroke in patients with atrial fibrillation. One year later the FDA gave its approval of the drug to prevent the recurrence of blood clots. However, according to The New York Times, an FDA panel voted against approving Xarelto for the treatment of acute coronary syndrome (ACS) (ii). Specifically, the panel was concerned that 15 percent of the participants in a study of Xarelto and ACS dropped out.

According to QuarterWatch, a report published by the Institute for Safe Medication Practices, the FDA received 356 adverse event reports of “serious, disabling, or fatal injury” for Xarelto in the first quarter of 2012 (iii). Additionally, the report stated that blood clots “were the predominant serious adverse events reported, accounting for 158 cases.” By October, the FDA had received 2,754 adverse event reports concerning Xarelto. Among these were 386 cases of pulmonary embolism, 279 cases of deep vein thrombosis, and 107 cases of gastrointestinal hemorrhage (iv).

The Xarelto infographic provides a summary of drug information and lists possible side effects. Additionally, it provides information on a study published in the New England Journal of Medicine, which found that the anticoagulant drug may increase the risk of hemorrhaging (v). Visit the Xarelto section of d’Oliveira & Associates website and view the infographic here.

If you or a loved one has suffered Xarelto side effects, you may want to speak with a lawyer regarding a claim. A personal injury lawyer familiar with new developments in the investigation of Xarelto may be able to assist you in making important personal and legal decisions. Our firm is working with some of the most experienced Xarelto lawyers in the country who are handling these cases.

Please contact the law offices of d'Oliveira & Associates, P.C. at 1-800-992-6878 or fill out a contact form for a free legal consultation.

(i) drugs.com/history/xarelto.html
(ii) nytimes.com/2012/05/24/business/fda-panel-votes-against-expansion-of-xarelto.html?_r=4&src=recg&
(iii) ismp.org/quarterwatch/pdfs/2012Q1.pdf
(iv) http://www.adverseevents.com/drugdetail.php?AEDrugID=5158&BrandName=XARELTO
(v) nejm.org/doi/full/10.1056/NEJMoa1111096

Read the full story at http://www.prweb.com/releases/2013/3/prweb10551499.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d'Oliveira & Associates Help New Bedford Woman Receive $95,000 in Damages for Dog Bite Injury Case #:NB-11736
2. d'Oliveira & Associates Helps Westport, MA Man Receive $100,000 Settlement for Reckless Driving Accident
3. d'Oliveira & Associates Helps Rhode Island Estate Receive the Maximum Compensation Under RI Law of $250,000 Settlement for Fatal Auto Accident
4. d'Oliveira & Associates Helps Newport Woman Receive $150,000 Settlement for Auto Accident; Case: MI-11889
5. The Law Firm of d'Oliveira & Associates Now Offers a No Win - No Fee Promise in Fosamax Cases
6. The Law Firm of d'Oliveira and Associates Now Offers a No Win - No Free Promise in Nexium Cases
7. d'Oliveira & Associates Notes the Announcement of Zoloft Birth Defects Multidistrict Litigation (MDL) Set to Start in Mid-September 2014
8. d'Oliveira & Associates Helps Fall River, MA Teenager Receive $38,500 in Auto Accident Settlement
9. D'Oliveira & Associates Now Offers a No Win No Fee Promise in Zithromax Cases
10. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
11. The Law Firm of d'Oliveira & Associates Now Offers a No Win - No Fee Promise in Mirena IUD Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... ... LLC and expands services in Northern Colorado. Aspire Autism, A Division of Autism ... Applied Behavior Analysis (ABA) services. Aspire provides center based Autism services in Broomfield ...
(Date:9/26/2017)... ... September 26, 2017 , ... DETECTO ... Effective October 1, 2017, the new agreement allows Premier members, at their discretion, ... scales. , “DETECTO is pleased to renew our agreement with Premier to be ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... “How to Live in the Millennium”: ... Satan and his minions are no longer a part of everyday life and do not ... we are and take responsibility for the thoughts, words, and actions that are chosen. ...
(Date:9/26/2017)... ... ... Ballad of Cowboy Justin”: a charming tale of a brave cowboy who saves the ... published author, Leah Westbrook, a wife and mother who loves to spend time with ... tale about a young brave cowboy, Cowboy Justin, who saves the town from a ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a Virginia Wanderer”: an ... help them relive their own youth. “Childhood Memories of a Virginia Wanderer” is the ... Navy for nine years. He received his BS from Idaho State University in ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Morgan Stanley ... Grand Hyatt hotel in New York.  Zimmer Biomet will ... Eastern Time. A live webcast of the ... website at http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... , Sept. 6, 2017 NeuroRx, a clinical ... Suicidal Ideation and Behavior (ASIB), has been granted Fast Track ... sequential therapy of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine ... a pivotal trial of this sequential therapy targeting patients who ... 1 ...
(Date:9/5/2017)... Sept. 5, 2017  Just 18 months after its ... pleased to announce the appointment of three new senior ... , Dominic Jones-Phillips and James Wright ... Tammy Wynne ... market access writers. She has over ten years, experience ...
Breaking Medicine Technology: